Maximum quantity allowed is 999
CAS RN: 56390-09-1 | Product Number: E0840
Epirubicin Hydrochloride
Purity: >95.0%(HPLC)
Size | Unit Price | Hyderabad | Japan* | Quantity |
---|---|---|---|---|
10MG |
₹6,500.00
|
3 | 38 |
|
50MG |
₹17,800.00
|
1 | 35 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | E0840 |
Purity / Analysis Method | >95.0%(HPLC) |
Molecular Formula / Molecular Weight | C__2__7H__2__9NO__1__1·HCl = 579.98 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Frozen (<0°C) |
Condition to Avoid | Heat Sensitive |
CAS RN | 56390-09-1 |
Reaxys Registry Number | 4229251 |
PubChem Substance ID | 468591676 |
Merck Index (14) | 3623 |
MDL Number | MFCD00941448 |
Appearance | Light yellow to Yellow to Orange powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Specific rotation | +310 to +340 deg(C=0.05, methanol)(calcd.on anh.substance) |
Water | max. 8.0 % |
Melting Point | 185 °C |
Specific Rotation | 310° (C=0.05,MeOH) |
Maximum Absorption Wavelength | 497(H2O) nm |
Solubility in water | Slightly soluble |
Solubility (slightly sol. in) | Methanol |
Pictogram | |
Signal Word | Danger |
Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H340 : May cause genetic defects. H350 : May cause cancer. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
RTECS# | QI9295750 |
Epirubicin has been shown to have a better toxicity profile than doxorubicin. The formation of glucuronide conjugates, not seen with doxorubicin, is observed with epirubicin. The reason for this is thought to be the inversion of the OH group at the 4' position in epirubicin, which facilitates the reaction of glucuronyl transferase. This facilitates excretion and may contribute to the reduced toxicity of epirubicin compared to doxorubicin.4) In clinical, epirubicin hydrochloride has been used alone or in combination with other cytotoxic chemotherapeutic agents in the treatment of a variety of malignancies. (The product is for research purpose only.)
References
- 1) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
- 2) Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
- 3) Epirubicin: is it like doxorubicin in breast cancer? A clinical review
- 4) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4’-epidoxorubicin
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.